Figure 3 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors

<p>IPH5201 treatment decreases tumoral CD39 enzymatic activity. The Wachstein–Meisel assay detects the presence of phosphates hydrolyzed from ATP due to enzymatic activity of CD39. <b>A,</b> Representative histology images of tumor tissues with reduction in CD39 enzymatic activity after treatment with IPH5201. <b>B,</b> Enzymatic activity was assessed by semi-quantitative scoring methodology for tumor, stroma, and vasculature. The pathologist conducted an overall assessment to determine whether a significant decrease was present on day 15 compared with screening biopsies.</p>

Authors

Publication Details

Published
2025-09-22
DOI
https://doi.org/10.1158/2767-9764.30177724
Primary Topic
Monoclonal and Polyclonal Antibodies Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Figure 3 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors

Meredith McKean, Vicky Barnhart, Eric Tu, Raymond Mager et al.
Monoclonal and Polyclonal Antibodies Research
article

Figure 3 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors

Meredith McKean, Vicky Barnhart, Eric Tu, Raymond Mager, Martina Imbimbo, Chunling Fan, Carine Paturel, Yun He, Steven Eck, Paula G. Fraenkel, Antoîne Italiano, Elina Murtomaki, Benedito A. Carneiro, Zachary A. Cooper, Patricia Martín-Romano, Teresa Macarulla, Antoine Hollebecque, John D. Powderly, Arsène‐Bienvenu Loembé, Eduardo Castañón Álvarez, Agnes Boyer Chamard
article en

Abstract

<p>IPH5201 treatment decreases tumoral CD39 enzymatic activity. The Wachstein–Meisel assay detects the presence of phosphates hydrolyzed from ATP due to enzymatic activity of CD39. <b>A,</b> Representative histology images of tumor tissues with reduction in CD39 enzymatic activity after treatment with IPH5201. <b>B,</b> Enzymatic activity was assessed by semi-quantitative scoring methodology for tumor, stroma, and vasculature. The pathologist conducted an overall assessment to determine whether a significant decrease was present on day 15 compared with screening biopsies.</p>

Openalex Percentile: Top 62%
Monoclonal and Polyclonal Antibodies Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Figure 3 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors — Meredith McKean, Vicky Barnhart, et al. · (2025) | TGRS Research Map | TGRS